பிரிவு ஆஃப் மார்பக புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரிவு ஆஃப் மார்பக புற்றுநோயியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரிவு ஆஃப் மார்பக புற்றுநோயியல் Today - Breaking & Trending Today

Agendia, Inc.: Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion


(1)
Agendia and Roche evaluate BluePrint s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced data from the APHINITY trial in a poster spotlight discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, titled
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial, outlines data from an exploratory analysis of the Phase 3 study that randomized 4,805 patients with histologically centrally confirmed HER2+ early breast cancer into two arms, one which received standard adjuvant chemotherapy and trastuzumab plus pertuzumab, and one which received standard adjuvant chemotherapy and trastuzumab plus placebo, for one year. The analysis was conducted in collaboration with Roche Pharmaceuticals. ....

United States , Ian Krop , Adam Brufsky , Terri Clevenger , Division Of Breast Oncology , University Of Pittsburgh School Medicine , Roche Pharmaceuticals , Magee Womens Cancer Program , Professor Of Medicine At Harvard Medical School , Agendia Inc , Dana Farber Cancer Institute , Hillman Cancer Center , Antonio Breast Cancer Symposium , Associate Chief , Breast Oncology , Associate Professor , Harvard Medical School , Medical Director , Cancer Center , Pittsburgh School , ஒன்றுபட்டது மாநிலங்களில் , ஈயந் க்ரொப் , டெர்ரி கிளெவெஞ்சர் , பிரிவு ஆஃப் மார்பக புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் பள்ளி மருந்து , ரோச் மருந்துகள் ,